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Abstract: Biomaterial scaffolds are a key part of cardiac tissue
engineering therapies. The group has recently synthesized a
novel polycaprolactone based polyurethane-urea copolymer
that showed improved mechanical properties compared with
its previously published counterparts. The aim of this study
was to explore whether indirect three-dimensional (3D) print-
ing could provide a means to fabricate this novel, biodegrad-
able polymer into a scaffold suitable for cardiac tissue
engineering. Indirect 3D printing was carried out through
printing water dissolvable poly(vinyl alcohol) porogens in
three different sizes based on a wood-stack model, into
which a polyurethane-urea solution was pressure injected.
The porogens were removed, leading to soft polyurethane-
urea scaffolds with regular tubular pores. The scaffolds were
characterized for their compressive and tensile mechanical
behavior; and their degradation was monitored for 12
months under simulated physiological conditions. Their com-
patibility with cardiac myocytes and performance in novel
cardiac engineering-related techniques, such as aggregate
seeding and bi-directional perfusion, was also assessed. The
scaffolds were found to have mechanical properties similar
to cardiac tissue, and good biocompatibility with cardiac
myocytes. Furthermore, the incorporated cells preserved their
phenotype with no signs of de-differentiation. The constructs
worked well in perfusion experiments, showing enhanced
seeding efficiency. VC 2016 Wiley Periodicals, Inc. J Biomed Mater
Res Part A: 00B:000–000, 2016.
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INTRODUCTION
According to the World Health Organization cardiovascular
diseases have been the leading cause of death globally,
claiming 17 million lives per year, more deaths than all can-
cers combined.1 Furthermore, the impact of cardiovascular
diseases is expected to grow further as the population
ages.2
With the currently available therapeutic options, very
few patients regain full cardiac function with no long-term
side effects following cardiovascular damage.3 Novel tissue
engineering based treatments promise to overcome these
limitations, by replacing injured cardiac tissue with artiﬁ-
cially created fully functioning muscle and/or inducing
endogenous cardiac regeneration.3
A key part of tissue engineered products are the bioma-
terial scaffolds. These are required to provide mechanical
support, and physical and biological cues for the viability,
differentiation and correct architecture of the artiﬁcial tissue
constructs.3 However, none of the currently used cardiac
scaffolds satisfy all of these requirements at the same time:
Some do not possess the required architecture, lacking uni-
form pore size and porosity, or mechanical properties in
correlation with that of heart tissue, while others are not
biodegradable or do not show sufﬁcient biocompatibility.3–5
Our group has recently synthesized a novel polycapro-
lactone (PCL) based polyurethane-urea (PUU) copolymer
with putrescine as the chain extender.6 Chain extenders are
low molecular mass compounds (hydroxyl and/or amine
terminated) that play an important role not only in the mor-
phology of segmented polyurethane (hard segments of these
elastomeric polymers are formed by the reaction between
the chain extender and di-isocyanate), but also during poly-
urethane degradation.7,8 Putrescine is a chemical compound
that is present during the natural growth and differentiation
of cells.9,10 Furthermore, its degradation products were
shown to have no toxicity to human endothelial cells.7
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Unlike other chain extenders, putrescine is eliminated dur-
ing the degradation of the PUU copolymer from the body
without interfering with its natural processes.7,11
The synthesized biodegradable PCL based PUU displayed
improved mechanical properties compared with its previ-
ously published counterparts; highly tailorable based on the
ratio of the incorporated hard (polyurethane) and soft
(PCL) segments.6 By optimizing this ratio, our group has
created a PUU copolymer that is capable of approximately
750% deformation before rupture, and possesses an elastic
modulus (70 kPa) ideal for the mechanically demanding
environment of cardiac tissue engineering applications.6
The aim of this study was to explore whether indirect
3D printing could provide a means to fabricate this novel
PCL based PUU polymer into a scaffold suitable for cardiac
tissue engineering.
Indirect 3D printing is a novel rapid prototyping tech-
nique, where, instead of the ﬁnal scaffold, a porogen is
printed, creating a sacriﬁcial mould, that is then later
removed after casting the polymer of interest around it.12
This method allows types of polymers, such as PUU, to be
3D printed into geometries that may not be achievable
using the direct approach.
Techniques based on porogens have been used to obtain
scaffolds for tissue engineering before, but these are lacking
the ordered architecture that cardiac applications require.13
In contrast, the indirect printing method it is ideally suited
for the controlled creation of the highly organized, aligned
micro-architecture and patient speciﬁc geometries that car-
diac tissue engineering requires that cannot be generated
with the traditional methods, such as solvent casting and
particle leaching.12–15
In this study, 3D printing was used to build porogens
from water dissolvable poly(vinyl alcohol) (PVA) with an
ordered architecture in three different sizes. This was fol-
lowed by the pressure-injection of a PUU solution into the
porogens. Finally, cylindrical-shaped pieces were cut and
immersed in water at room temperature to dissolve the
porogen during at least three days.
PUU scaffolds were thus obtained in three different
sizes: to contain 300, 400, and 500 lm channels (denoted
as PUU-S300; PUU-S400, and PUU-S500, respectively). The
generated scaffolds were characterized for their compres-
sive and tensile mechanical behavior; their degradation
under simulated physiological conditions was monitored for
12 months; and their architecture, and its correlation to the
original porogen structure, was examined using scanning
electron microscopy. This was followed by an assessment of
the scaffolds performance in cardiac tissue engineering
applications, by examining their compatibility with cardiac
myocytes and novel cardiac engineering-related techniques,
such as aggregate seeding and bi-directional perfusion.
MATERIALS AND METHODS
The synthesis of polyurethane-urea
The polymerization of segmented PUU was carried out at
608C under constant stirring. A solution of PCL-diol (poly-
caprolactone diol, Mn  2000, Sigma Aldrich, St. Louis, MO)
and HMDI (4,40-Methylenebis(cyclohexyl isocyanate), Sigma
Aldrich, St. Louis, MO) in DMF (N,N0-dimethylformamide,
Sigma Aldrich, St. Louis, MO) (80% w/v) was placed in a
three- neck reactor with Sn-octoate (Sigma Aldrich, St.
Louis, MO) (0.2%) for 3 hours. The solution was allowed to
cool down to room temperature, after which putrescine
(1,4-diaminobutane, Sigma Aldrich, St. Louis, MO) was
added drop wise under vigorous stirring, keeping the reac-
tion at room temperature for 1 hour. Finally, the solution
was re-heated to 608C for 1 hour and poured into distilled
water, forming a white precipitate. After 30 min, the poly-
mer was removed, washed repeatedly with an ethanol/
water mixture (75:25, v/v), and dried under vacuum for
24 h at 608C. The molar proportion of (PCL-diol: HMDI:
putrescine) was (1:2:1).
Fourier transform infrared (FTIR) spectroscopy and
molecular mass. FTIR spectroscopy and gel permeation
chromatography (GPC) were performed to verify the correct
synthesis of PUU. Infrared spectrum was obtained in a Nico-
let Protege 460 FTIR spectrometer. Spectra were collected
using a ﬁlm over a KBr tablet; samples were scanned from
4000 to 500 cm21. Polymer molecular mass (Mw) was
determined in an Agilent Gel Permeation Chromatograph
(GPC) model 1100, with DMF (HPLC grade) as the eluent, at
1 mL/min at 508C. Polystyrene was used as the standard.
Mechanical testing. Rectangular samples (50 3 5 3
0.1 mm) were cut from ﬁlms of the synthesized PUU, and
placed under tension until rupture in a Shimadzu universal
testing machine model AGS-X. The crosshead speed was
100 mm/min, and a load cell of 1000N was employed. Elas-
tic modulus (E), ultimate strength (ru), and ultimate defor-
mation (eu) were calculated.
The design and fabrication of the porogens
The 3D CAD models of a “woodpile structure” were gener-
ated in three different sizes in the OpenSCAD software and
converted into the “STL” ﬁle format. The woodpile architec-
ture was chosen, as it was hypothesized to lead to a scaffold
morphology favorable to cardiac tissue. The three different
sizes were created to enable the generation of scaffolds
with pore sizes of approximately 300, 400, and 500 lm.
Porogens were fabricated based on these three models
using a Replicator 3D printer (Makerbot, Brooklyn, NY) and
polyvinyl alcohol (PVA) ﬁlaments. PVA was selected as the
material for the porogens due to its high water solubility,
biodegradability and biocompatibility,16 and as it has been
previously used for tissue engineering applications.17
Scaffold fabrication
PUU was dissolved in DMF at 1008C for 3 h under constant
stirring. The solution was poured over the porogen in a
mould and injected using a nitrogen gas injection system at
4.92 kgcm2. The injected polymer was allowed to cool down
to room temperature. Scaffolds samples were cut into cylin-
ders (Ø10 3 5mm) and dried under vacuum at 608C for
24 h. The PVA porogen was completely removed by placing
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the scaffold into distilled water, performing two water
changes over a 3-day period. Finally, samples were soni-
cated for 10 minutes to remove any remaining PVA. The
samples were dried at room temperature for 1 week, and
then dried at 608C under vacuum for 24 h prior to
characterization.
Scaffold characterization
Scanning electron microscopy (SEM) and pore size
determination. In order to characterize the morphology of
the deposited porogen ﬁbers and the architecture of the
PUU scaffolds, samples were coated with gold and visual-
ized under a JEOL JSM-59101LV electron microscope. At
least three SEM micrographs were taken at different zones
of ﬁve of each scaffold type and representative morpholo-
gies were reported. Pore size was calculated by at least 20
measures of pores in SEM images, by using the ImageJ anal-
ysis software. The area of each pore was measured and
then was parameterized to a circular area, to obtain an
equivalent diameter, which is called the pore size. Mean and
standard deviation values are reported.
Compression and tensile mechanical testing. The com-
pression testing of the PUU scaffolds was performed in an
Instron 3344 universal testing machine at 1 mm/min until
50% strain using a 100N load cell. Cylindrical-shaped sam-
ples (5 mm 3 10 mm, H 3 Ø) were used for each test
(n5 5). The load was applied along the longitudinal pore
direction. Two conditions of PUU scaffolds were tested:
dried and wet (48 h in phosphate buffered saline). The com-
pressive secant modulus was calculated at 20% strain (E20),
as this is the typical level of deformation applied in mechan-
ically stimulated tissue cultures.18
Tensile testing was performed in a Shimadzu universal
testing machine model AGS-X with a load cell of 100N. This
experiment was carried out in order to evaluate the elastic
modulus of the samples by applying the load in the XY and
the XZ planes. About 30 mm high samples with a 5 mm 3
5 mm base were used for XZ plane tests, while 5 mm 3
5 mm base 3 15 mm high specimens were applied in XY
plane measurements. The scaffolds were initially strained to
30% of their original length in order to calculate the secant
modulus at 20% deformation, and to measure the residual
deformation of the samples in both planes. A strain rate of
2 mm/min was used for samples in the XZ plane, and
1 mm/min was applied in the XY plane. The same samples
were used to evaluate the scaffolds’ mechanical behavior up
to breaking. A crosshead speed of 50 mm/min was used in
the XZ plane, and of 20 mm/min in the XY plane. The elastic
modulus (20% strain, E20), maximum tensile strength (ru),
and the elongation at rupture (eu) were determined.
Porosity. The density of the PUU and the porosity of the
scaffolds were measured using a Mettler Toledo density kit
based on the Archimedes principle of buoyancy.19
Degradation under static simulated physiological
conditions. This experiment was conducted to measure how
the molecular weight (Mw) of the PUU, and the elastic mod-
ulus and mass of the scaffolds change during 12 months
under simulated physiological conditions. Samples (n5 3) of
PUU-S300 were used. Mw measurements were performed
on Ø10 3 5 mm cylindrical samples using GPC each month.
The mass of the scaffolds was measured at the start, and
during each month, of the experiment. Elastic modulus tests
(sample size was 10 3 10 mm, Ø 3 H) were performed
every 3 months. Samples were placed in vials with 5 mL of
PBS (pH 7.4) with 0.05% of TWEENV
R
20 at 378C. PBS was
changed every week.
In order to determine, whether degradation would com-
promise with time the scaffolds’ ability to function in the
demanding mechanical environment of the heart, the elastic
modulus of the scaffolds was tested using a Perkin Elmer
DMA-7 dynamic mechanical analyzer in compression mode.
Isothermal tests were conducted at 378C, with a frequency
sweep between 0.5 and 10 Hz. The static load was 200 mN
and dynamic load was 50 mN. Elastic modulus was deter-
mined at 2 Hz, which is a frequency similar to the normal
cardiac rhythm.
Suitability for cardiac tissue engineering
In order to assess the scaffolds’ practical suitability for car-
diac tissue engineering, the scaffolds were tested for bio-
compatibility and in novel cardiac tissue engineering related
techniques: cell aggregate seeding and bi-directional
perfusion.
Scaffold pre-treatment. Prior to cell seeding, PUU scaffolds
were sterilized using ethanol, antibiotics, and UV exposure.
Cardiac myocyte adhesion and viability. Primary human
cardiac myocytes (HCMs) were obtained commercially (Pro-
mocell, Germany) and cultured in myocyte growth media
(MGM) (Promocell, Germany) at 5% CO2 and 378C. Cells
were sub-cultured when reaching 80% conﬂuence, and used
for experiments at passage 5.
In order to determine whether uncoated PUU can pro-
vide a suitable adhesion site alone, or whether pre-coating
with extracellular matrix molecules is necessary, cardiac
myocytes were cultured on uncoated and ﬁbronectin coated
400 lm PUU scaffolds (n5 3), and assayed using the Presto
Blue technique after 24 h.
This initial test of cell adhesion, was followed by more
thorough examination of whether the scaffolds can maintain
the viability of the cells, and whether channel size might
have an inﬂuence on this. 300, 400, and 500 lm scaffolds
were incubated with ﬁbronectin (50 lg/mL, Sigma Aldrich,
UK) and seeded with 100 lL of MGM containing 1 3 105
cells (n53). For the controls, the same amount of cells was
seeded directly into the wells of a standard culture plate.
After 1 hour of incubation, 1 mL of MGM was added to each
sample, which were then cultured at 378C and 5% CO2 for
90 min and 24 hours. The Presto Blue cell viability and the
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PicoGreen cell number assays were used for the evaluation
of the samples.
Cell aggregate seeding. Cell aggregates were obtained by
trypsinization and incubation of HCMs in GravityPLUS plates
(Insphero, Switzerland). Fibronectin coated scaffolds were
seeded either by cell suspension (CS) or by cell aggregates
(CA) at 4 3 104 cells per scaffold (equivalent to 23 cell
aggregates per scaffold), as this is the recommended cell
number that allows viable cell aggregates to form that are
optimal for seeding. The seeded scaffolds were cultured up
to seven days, with time points at day 3 and day 7 for Cell-
Tracker imaging, cardiac a-actin staining, and the PicoGreen
assay (n5 3).
Bi-directional perfusion seeding. PUU scaffolds were steri-
lized and coated with ﬁbronectin, after which they were
placed in a TEB-1000 perfusion bioreactor (Ebers, Spain).
The scaffolds were seeded with 10,000 cells per scaffold in
duplex mode at 0.1 mL/s ﬂow rate. Static seeded scaffolds
were used as the control. Post-seeding, the scaffolds were
incubated for 2 hours, and assayed using the Presto Blue kit
and SEM (n52) in order to examine the efﬁciency of the
seeding.
Biological assays
Cell viability: Presto blue assay. Scaffolds were placed into
a fresh 24-well plate, washed with PBS and incubated in a
10% solution of Presto Blue at 378C for 30 min. The solu-
tion was transferred into a 96-well plate in replicates, and
absorbance was measured in a plate reader at 570 nm exci-
tation and 600 nm emission.
Cell numbers: Picogreen assay. Cell numbers in the seeded
scaffolds were measured using the Quant-iT PicoGreen
dsDNA Assay kit (Life Technologies, The United States). The
scaffolds were placed in Eppendorf tubes and 1 mL of 13
TE buffer (included in kit) was added per sample. The sam-
ples were frozen at 2808C, followed by two cycles of
freeze–thaw in order to ensure the complete lysis of the
cells. About 100 lL of the lysate was added to wells of 96-
well plates and mixed with 100 lL of the stain solution
(prepared according to the manufacturer’s instruction). Flu-
orescence was read at 485 nm excitation and 528 nm
emission.
CellTracker imaging. In order to track the cells’ adhesion
to the scaffolds, HCMs were dyed with CellTracker Green
(Life Technologies, The United States), a non-toxic stable ﬂu-
orescent probe that is transferred to daughter cells, and
were imaged using a confocal microscope (Leica TCS SPE,
Germany).
Cardiac a-actin staining. Cellular phenotype was con-
ﬁrmed through cardiac a-actin staining, a marker for
contractile heart muscle cells,20 using mouse anti-cardiac-a-
actin (Sigma-Aldrich, The United Kingdom) and a goat anti-
mouse Alexa ﬂuor 555 secondary antibody. Nuclear staining
was performed using Vectashield-DAPI (Vector Laboratories,
#H-1500).
Statistical analysis
Results are represented as mean6 standard deviation, and
were analyzed using One-way ANOVA with Tukey’s post-test
and Two-way ANOVA followed by Bonferroni’s post-test
(Minitab v16.1, GraphPad Prism v5). A “p” value equal to, or
smaller than, 0.05 was considered signiﬁcant.
RESULTS
Polyurethane-urea
FTIR spectroscopy of the synthesized polymer conﬁrmed
that it is PUU (Fig. 1), with the pronounced carbonyl peak
of the ester in the urethane groups and in the soft segment
at 1735 cm21, and a shoulder peak at 1630 cm21 attribut-
able to the urea carbonyl groups. The urethane and urea
groups also showed absorbance at 3360 cm21. The absorb-
ance at 1100 cm21 was attributed to the ether in the soft
segment. The absence of a peak at 2267 cm21 indicated the
lack of unreacted isocyanate groups.
The mechanical properties and molecular mass of the
PUU are shown in Table I. The synthesized polymer proved
to be highly deformable and to have a low elastic modulus,
giving it good mechanical properties for soft tissue engi-
neering applications.
Scaffold characterization
Scanning electron microscopy. Examination of the poro-
gens under SEM has shown that the frameworks printed
out of 300 and 400 lm ﬁbers (Fig. 2) were completely
aligned. However, those printed to provide 500 lm channels
displayed a distorted morphology: The newly deposited
TABLE I. Tensile and Physicochemical Properties of the Syn-
thesized Segmented PUU
Elastic modulus (E) 5.766 2.85 MPa
Ultimate strength (ru) 30.136 7.43 MPa
Ultimate deformation (eu) 692.466 78.76 %
Contact angle 92.56 2.9 8
Molecular weight 7.2455 3 105 g/mol
FIGURE 1. FTIR spectrum of the synthesized PUU polymer.
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porogen ﬁbers bent around the already consolidated ones,
creating a wavy ﬁber morphology.
SEM images of the scaffolds (Fig. 2) show a network of
aligned channels in the XZ and YZ planes, connected by rec-
tangular pores in the XY plane, in case of the 300 and 400
lm pore PUU scaffolds.
The 500 lm scaffolds contained semi-aligned channels
in the XZ and YZ planes that, unlike with the other two scaf-
fold types, do not provide an unobstructed straight path
through the scaffold. In the XY plane, instead of the rectan-
gular pores observed with the 300 and 400 lm scaffolds, a
random architecture was detected without any visible orien-
tation or alignment.
The inner walls of the channels displayed a rough, irreg-
ular morphology with micro-pores along the surface in the
case of all three scaffold types.
Mechanical properties. Figure 3 shows the mechanical
behavior of the three different scaffold types under both
dry and wetted conditions during compression testing. The
recorded curves display the three typical stages of the com-
pression of porous materials. Elastic bending of the pore
walls in the scaffolds is present in the ﬁrst stage (from 0%
to 20% of strain); followed by a plateau dominated by elas-
tic buckling of the pore walls; ﬁnally, an increase in stiffness
is shown as a result of the collapse of the foam structure.21
The compressive modulus of the 300 and 400 lm chan-
nel scaffolds was found not to be statistically different.
However, the value was observed to drop from approxi-
mately 11 to 4–7 kPa once the scaffolds were wetted. The
500 lm scaffolds displayed a signiﬁcantly higher compres-
sive modulus compared with its two counterparts, with a
value of approximately 15.6 kPa when dry, and 13.3 kPa
when wetted.
The scaffolds displayed anisotropic behavior under ten-
sion, with higher stiffness (an elastic modulus of 132 kPa)
in the XZ plane (perpendicular to the direction of the chan-
nels), and higher elasticity (elastic modulus of 15 kPa) in
the XY plane (parallel to the channels). The ultimate defor-
mation that the scaffolds reached was not statistically differ-
ent between the two planes. The residual strain of the
scaffolds subjected to a 39% strain was less than 3%.
Porosity. Porosity measurements (Table II) have shown that
not only the diameter of the channels, but also the variabili-
ty of the pores sizes, increased with the thickness of the
porogens. The greatest variability in pore size was detected
in the case of the 500 lm scaffolds. This was probably due
to the deformation and misalignment of the ﬁbers as
detected by SEM.
Degradation. The molecular mass of polymer was reduced
by one order of magnitude (from 105 to 104 g/mol) during
the 12-month period (see Fig. 4), whereas the mass loss
remained practically unchanged (lower than 5%). This fact
could be attributed to an induction phase of degradation, in
which the polymers undergo random scission of chains
without signiﬁcant loss of physical mass. The degradation
kinetics of segmented polyurethane depends on the poly-
mer’s chemical structure. In other words, depends upon the
reagents used during synthesis of the PUU, that is, the type
of chain extender, the type of isocyanate or polyol, and/or
the synthesis conditions. The ﬁndings of this study regard-
ing the degradation kinetics of PUU are similar to those pre-
sented in the scientiﬁc literature.22,23
FIGURE 2. SEM images of the PVA porogens in the three different sizes (above) and the PUU scaffolds (below) that they generated. The dis-
played images were taken of the XY plane of the porogens/scaffolds (parallel to the fiber/channel direction). The stacks of 300 and 400 lm thick
porogens created aligned channels in the PUU scaffolds. The 500 lm thick porogens deformed under their own weight, resulting in a distorted
scaffold architecture. The scale bar represents 500 lm.
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The dynamic mechanical evaluation of the samples dem-
onstrated an increase in the storage modulus (E0) of the
scaffolds from 1.5 to 2.8 MPa by the end of month 12.
Suitability for cardiac tissue engineering
Cardiac myocyte adhesion and viability. After 24 hours of
static culture ﬁbronectin coated scaffolds showed 94% via-
bility (Fig. 5), while uncoated scaffolds produced a signiﬁ-
cantly reduced value of 65%, compared with two-
dimensional (2D) tissue culture plastic controls. Therefore,
in all following experiments the scaffolds were pre-coated
with ﬁbronectin before use.
When comparing the cellular adhesion to the three dif-
ferent scaffold types and to 2D tissue culture plastic con-
trols, no signiﬁcant difference was found between the
scaffolds and the control samples after 90 min and 24 h
(Fig. 6).
Cell aggregate seeding. CellTracker ﬂuorescent staining
revealed that the cells have spread out across the scaffolds
in a near homogenous manner with both suspension and
aggregate seeding strategies.
Cell aggregate seeded scaffolds showed signiﬁcantly
higher cell numbers (p< 0.001) at day 3 and 7 compared
FIGURE 3. The compression and tensile mechanical properties of the PUU scaffolds: The compression stress-strain curves (A) and moduli (B) of
all three scaffold types under both dry and wet conditions. The tensile stress–strain curve (C), elastic modulus and tensile strength (D) of a 400
lm scaffold in both the XY (parallel to channels) and XZ (perpendicular to channels) planes. Statistically significant differences (p< 0.05) are
denoted by the “*” symbol.
TABLE II. The Porosity of all Tree Scaffold Types
Parameter Unit PUU-S300 PUU-S400 PUU-S500
Average pore diameter (XZ plane) lm 338.546 140.78 433.036 144.75 478.266 251.79
Average pore diameter (XY plane) lm 363.226 30.44 517.986 57.90 599.936 319.93
Overall porosity (%) 96.336 0.69 92.576 0.66 92.046 1.13
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with cell suspension seeded samples and two dimensional
tissue culture plastic (TCP) control cultures (Fig. 7). Fur-
thermore, the cells in these scaffolds appeared to grow into
the channels, leaving the walls of the scaffold. The cells
seeded in suspension, although less proliferative than the
aggregate cultures, performed equivalently to TCP controls.
Furthermore, suspension seeded cells appeared to form lon-
ger and more mature myoﬁbers than the aggregates, indi-
cating the possibility of generating a more functional tissue
construct. Immunostaining of the scaffolds for cardiac a-
actin showed that the cells have maintained their phenotype
with both seeding methods during the seven days of the
culture (Fig. 8).
Bi-directional perfusion seeding. Bi-directional perfusion
markedly increased the seeding efﬁciency in the case of all
three scaffold types compared with static controls (Fig. 9).
The difference between static and perfused samples was
largest in the case of the 500 lm scaffolds, showing a 1.5
times greater average efﬁciency in favor of perfusion. SEM
has demonstrated that, in contrast with static cultures,
where cells remained more toward the surface, cells pene-
trated deeper into the scaffolds with perfusion, adhering to
the walls of the channels.
DISCUSSION
The aim of this study was to explore whether indirect 3D
printing can be used as a method for fabricating a novel
PUU variant into scaffolds suitable for cardiac tissue
engineering.
A wood stack structure was chosen as the basis of the
porogens, as it would yield an anisotropic structure of
aligned channels. Such architecture was hypothesized to
provide excellent support for the formation of cardiac myo-
ﬁbrils; promote homogenous tissue growth trough excellent
nutrient/waste exchange; and to provide a means to mimic
the anisotropic mechanical properties of heart muscle.
SEM of the scaffolds has demonstrated that this architec-
ture was successfully created through indirect printing. The
size of the channels in the PUU structures correlated well
with the thickness of the printed PVA ﬁlaments on average,
however there was a relatively large standard deviation (in
the range of 6140–200 lm) present. This was largest with
the 500 lm scaffolds, which is understandable considering
that, as the SEM images have shown, the PVA ﬁlaments at
this thickness were unable to support their weight and col-
lapsed, generating a distorted scaffold morphology. The
FIGURE 4. The degradation of PUU scaffolds under simulated physio-
logical conditions monitored in terms of mass loss (left axis, clear
circles) and molecular weight (right axis, full squares) up to 12
months.
FIGURE 5. The viability of cardiac myocytes after 24 h on fibronectin
coated and uncoated PUU scaffolds, and 2D tissue culture plastic con-
trols was tested using the PrestoBlue assay (n53). Statistically signifi-
cant differences (p< 0.05) are denoted by the “*” symbol.
FIGURE 6. DNA content of all three PUU scaffold types and tissue cul-
ture plastic (TCP) controls after both 90 min and 24 h (n5 3).
FIGURE 7. DNA concentration in cell suspension and cell aggregate
seeded PUU scaffolds and in TCP control samples after three and
seven days of culture (n53). The scaffolds and controls were seeded
under static conditions. Statistically significant differences (p< 0.05)
are indicated by the “*” symbol.
ORIGINAL ARTICLE
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH A | MONTH 2016 VOL 00A, ISSUE 00 7
distortion highlights the fact that there are some limitations
to this rapid prototyping technique, and that the mechanical
properties of the porogen material has to be kept in mind
when choosing the geometry of the scaffold.
A requirement for any cardiac scaffold that it should
offer no resistance to the muscle’s contraction during the
systole, while providing mechanical support to the tissue
against the tensile stresses of the diastolic phase.24 The cre-
ated scaffolds fulﬁll both of these criteria: The elastic modu-
lus of 15–132 kPa displayed by the scaffolds under tension
ﬁts well into the range measured for cardiac muscle 20–500
kPa,24 and resides within the interval (7.9–1200 kPa) that
has been reported in previous cardiac biomaterial
studies.25–30
Furthermore, thanks to the low compression modulus
shown by the wetted scaffolds (4–13.5 kPa), it is expected
that the constructs will offer very little resistance to the
contraction of the cardiomyocytes. Additionally, it is also
expected that the scaffolds will not lose their geometry once
in use, as they are capable of almost completely regaining
their original shape even after high levels of deformation,
demonstrated by the very low residual strain (3%) remain-
ing in the samples after stretching them by 39%.
The scaffolds degraded slowly, losing only 5% of their
mass by the end of a 12-months period. However, these val-
ues are not unlike that of the currently commercially avail-
able counterparts. For example, the polyurethane based
thumb joint implant, Artelon Artimplant, requires 6 years to
break down in vivo.6 Furthermore, considering that the
molecular weight of the PUU has dropped to almost one
tenth of its original value by the end of the 12 months, it is
highly likely that the scaffolds will erode much faster once
exposed to the constant compression-tension cycles present
in the mechanically demanding environment of the heart
muscle.
The PUU scaffolds displayed good biocompatibility,
maintaining cardiac myocyte viability equivalently to tissue
culture plastic once coated with ﬁbronectin. Cell numbers
were reduced in all scaffold types after 24 h compared with
tissue culture plastic controls, however this was found not
to be statistically signiﬁcant, and is not unlike the ﬁndings
of similar PU studies.31 On the other hand, in cell aggregate
seeding experiments the scaffold samples showed higher
proliferation compared with TCP controls at both time
FIGURE 8. Confocal microscopy images of cardiac a-actin (a marker of cardiac myocytes) and DAPI (cell nucleus) stained sections of cell suspen-
sion and cell aggregate seeded PUU scaffolds after 3 and 7 days in culture. The scale bar represents 25 lm.
FIGURE 9. The efficiency of bi-directional perfusion compared with
static seeding in the case of all three scaffold types measured using
the PrestoBlue assay (n52). Statistically significant differences
(p< 0.05) are indicated by the “*” symbol.
8 HERNANDEZ-CORDOVA ET AL. INDIRECT THREE-DIMENSIONAL PRINTING OF CARDIAC SCAFFOLDS
points, containing three times as much cells after 3 days
and twice as much after 7 days. This not only demonstrates
that the cells are capable of recovering after an initial
period of low proliferation, but also emphasizes the beneﬁts
of cell aggregate seeding and the excellent compatibility of
the PUU scaffolds with this novel technique. Fluorescent
imaging showed that the cells have spread out evenly across
the scaffold. This is signiﬁcant considering that with most
scaffolds, cells tend to distribute in a heterogeneous manner,
favoring the surface of the constructs.32,33
Furthermore, the cells maintained their contractile myo-
cardial phenotype up until 7 days, as demonstrated by car-
diac a-actin staining, showing that PUU is capable of
maintaining not only viability, but also differentiation. The
scaffolds performed well in perfusion experiments, display-
ing no limitation in this regard. Interestingly, perfusion
seeding made the greatest difference in the case of the 500
lm scaffolds. This is understandable, however, as the dis-
torted geometry of this scaffold type, although makes cell
penetration more difﬁcult under static condition, is beneﬁ-
cial for capturing cells once perfused. However, the intricate
internal morphology of the distorted 500 lm scaffolds is
not beneﬁcial considering the requirements of cardiac tissue
engineering post-seeding, where it may disrupt uniform
medium ﬂow through the scaffold and block the formation
of myoﬁber strands. In contrast, the uniform channels and
even porosity of the PUU-S300 and 400 scaffolds are ideally
suited for this,34 making them promising candidates as car-
diac scaffolds.
CONCLUSIONS
In summary, our ﬁndings demonstrate the potential of com-
bining indirect rapid prototyping and elastomeric seg-
mented polyurethane-urea as a means to fabricate soft
scaffolds with controlled 3D micro-architecture and pore
size for cardiac tissue engineering.
The produced scaffolds were found to have excellent
mechanical properties, being strong enough to withstand
the tensile stresses of the diastole, while offering very little
resistance to the contraction of the tissue during systole.
The material showed good biocompatibility with cardiac
myocytes, outperforming tissue culture plastic in term of
cell numbers after only three days in culture. Furthermore,
the cells incorporated into the scaffolds preserved their con-
tractile myocardial phenotype with no signs of de-
differentiation. The constructs worked well in perfusion
experiments, showing enhanced seeding efﬁciency.
Further in vitro investigations will follow, combining
aggregate seeding, perfusion, and mechanical stimulation in
longer-term experiments, and testing additional geometries,
in order to provide further evidence of the potential that
this biomaterial and novel scaffold fabrication technique has
for cardiac tissue engineering.
ACKNOWLEDGMENT
To Consejo Nacional de Ciencia y Tecnologıa (CONACYT),
Mexico, by schorlarship to Roberto Hernandez-Cordova, and to
Consejo de Ciencia, Innovacion y Tecnologıa del Estado de
Yucatan (CONCITEY) by ﬁnancial support for Research Project
Grants, FOMIX-170132. The authors would like to thank Mr
Glen Ferris for his technical support.
REFERENCES
1. Chiu LLY, Radisic M. Cardiac tissue engineering. Curr Opin Chem
Eng 2013;2:41–52.
2. Barton P, Andronis L, Briggs A, McPherson K, Capewell S. Effec-
tiveness and cost effectiveness of cardiovascular disease preven-
tion in whole populations: Modelling study. BMJ 2011;343:d4044.
3. Taylor DA, Sampaio LC, Gobin A. Building new hearts: A review
of trends in cardiac tissue engineering. Am J Transplant 2014;14:
2448–2459.
4. Boffito M, Sartori S, Ciardelli G. Polymeric scaffolds for cardiac
tissue engineering: Requirements and fabrication technologies.
Polym Int 2014;63:2–11.
5. Generali M, Dijkman PE, Hoerstrup SP. Bioresorbable scaffolds for
cardiovascular tissue engineering. EMJ Int Cardiol 2014;1:91–99.
6. May-Hernandez L, Hernandez-Sanchez F, Gomez-Ribelles JL,
Sabater Serra R. Segmented poly(urethane-urea) elastomers
based on polycaprolactone: Structure and properties. J Appl
Polym Sci 2011;119:2093–2104.
7. Guan J, Sacks MS, Beckman EJ, Wagner WR. Synthesis, charac-
terization, and cytocompatibility of elastomeric, biodegradable
poly(ester-urethane)ureas based on poly(caprolactone) and
putrescine. J Biomed Mater Res 2002;61:493–503.
8. Hong Y, Guan J, Fujimoto KL, Hashizume R, Pelinescu AL,
Wagner WR. Tailoring the degradation kinetics of poly(ester-car-
bonate urethane)urea thermoplastic elastomers for tissue engi-
neering scaffolds. Biomaterials 2010;31:4249–4258.
9. Tabor CW, Tabor H. 1,4-diaminobutane (putrescine), spermidine
and spermine. Annu Rev Biochem 1976;45:285–306.
10. Cauich-Rodrıguez JV, Chan-Chan LH, Hernandez-Sanchez F,
Cervantes-Uc JM. Degradation of polyurethanes for cardiovascular
applications. In: Pignatello R, editor. Advances in Biomaterials Sci-
ence and Biomedical Applications. Croacia: InTech; 2013. p 51–82.
11. Guan J, Sacks MS, Beckman EJ, Wagner WR. Biodegradable pol-
y(ether ester urethane)urea elastomers based on poly(ether ester)
triblock copolymers and putrescine: Synthesis, characterization
and cytocompatibility. Biomaterials 2004;25:85–96.
12. Park JH, Jung JW, Kang HW, Cho DW. Indirect three-dimensional
printing of synthetic polymer scaffold based on thermal molding
process. Biofabrication 2014;6:1–10.
13. Lebourg M, Sabater Serra R, Mas Estelles J, Hernandez-Sanchez F,
Gomez-Ribelles JL, Suay Anton J. Biodegradable polycaprolactone
scaffold with controlled porosity obtained by modified particle-
leaching technique. J Mater Sci: Mater Med 2008;19:2047–2053.
14. Yeong W-Y, Chua C-K, Leong K-F, Chandrasekaran M. Rapid pro-
totyping in tissue engineering: Challenges and potential. Trends
Biotechnol 2004;22:643–652.
15. Yeong WY, Sudarmadji N, Yu HY, Chua CK, Leong KF,
Venkatraman SS, Boey YC, Tan LP. Porous polycaprolactone scaf-
fold for cardiac tissue engineering fabricated by selective laser
sintering. Acta Biomater 2010;6:2028–2034.
16. Ghanbarzadeh B, Almasi H. Biodegradable polymers. In: Chamy
R, Rosenkranz F, editors. Biodegradation – Life of Science. Rijeka:
InTech; 2013. p 141–185.
17. Vrana NE, Liu Y, McGuinness GB, Cahill PA. Characterization of
poly(vinyl alcohol)/chitosan hydrogels as vascular tissue engi-
neering scaffolds. Macromol Symp 2008;269:106–110.
18. Akhyari P, Fedak PWM, Weisel RD, Lee T-YJ, Verma S, Mickle
DAG, Li R-K. Mechanical stretch regimen enhances the formation
of bioengineered autologous cardiac muscle grafts. Circulation
2002;106:I-137–I-142.
19. Pickover C. Archimedes to Hawking: Laws of Science and the
Great Minds Behind Them. Oxford: Oxford University Press; 2008.
528 p.
20. M€uller M, Mazur AJ, Behrmann E, Diensthuber RP, Radke MB, Qu
Z, Littwitz C, Raunser S, Schoenenberger C-A, Manstein DJ,
Mannherz HG. Functional characterization of the human a-cardiac
actin mutations Y166C and M305L involved in hypertrophic car-
diomyopathy. Cell Mol Life Sci 2012;69:3457–3479.
ORIGINAL ARTICLE
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH A | MONTH 2016 VOL 00A, ISSUE 00 9
21. Gibson LJ, Ashby MF, Harley BA. Cellular Material in Nature and
Medicine. Cambridge: Cambridge University Press; 2010. 309 p.
22. Chan-Chan LH, Solis-Correa R, Vargas-Coronado RF, Cervantes-
Uc JM, Cauich-Rodrıguez JV, Quintana P, Bartolo-Perez P. Degra-
dation studies on segmented polyurethanes prepared with HMDI,
PCL and different chain extenders. Acta Biomater 2010;6:2035–
2044.
23. Chan-Chan LH, Tkaczyk C, Vargas-Coronado RF, Cervantes-Uc JM,
Tabrizian M, Cauich-Rodriguez JV. Characterization and biocom-
patibility studies of new degradable poly(urea)urethanes prepared
with arginine, glycine or aspartic acid as chain extenders. J Mater
Sci: Mater Med 2013;24:1733–1744.
24. Chen Q-Z, Bismarck A, Hansen U, Junaid S, Tran MQ, Harding
SE, Ali NN, Boccaccini AR. Characterisation of a soft elastomer
poly(glycerol sebacate) designed to match the mechanical proper-
ties of myocardial tissue. Biomaterials 2008;29:47–57.
25. Courtney T, Sacks MS, Stankus J, Guan J, Wagner WR. Design
and analysis of tissue engineering scaffolds that mimic soft tissue
mechanical anisotropy. Biomaterials 2006;27:3631–3638.
26. Chimenti I, Rizzitelli G, Gaetani R, Angelini F, Ionta V, Forte E,
Frati G, Schussler O, Barbetta A, Messina E, Dentini M,
Giacomello A. Human cardiosphere-seeded gelatin and collagen
scaffolds as cardiogenic engineered bioconstructs. Biomaterials
2011;32:9271–9281.
27. Ara~na M, Pe~na E, Abizanda G, Cilla M, Ochoa I, Gavira JJ,
Espinosa G, Doblare M, Pelacho B, Prosper F. Preparation and
characterization of collagen-based ADSC-carrier sheets for cardio-
vascular application. Acta Biomater 2013;9:6075–6083.
28. Chan V, Raman R, Cvetkovic C, Bashir R. Enabling microscale and
nanoscale approaches for bioengineered cardiac tissue. ACS
Nano 2013;7:1830–1837.
29. Fleischer S, Feiner R, Shapira A, Ji J, Sui X, Wagner HD, Dvir T.
Spring-like fibers for cardiac tissue engineering. Biomaterials
2013;34:8599–8606.
30. Godier-Furnemont AFG, Martens TP, Koeckert MS, Wan L, Parks
J, Arai K, Zhang G, Hudson B, Homma S, Vunjak-Novakovik G.
Composite scaffold provides a cell delivery platform for cardio-
vascular repair. Proc Natl Acad Sci U S A 2011;108:7974–7979.
31. Chiono V, Mozetic P, Boffito M, Sartori S, Gioffredi E, Silvestri A,
Rainer A, Giannitelli SM, Trombetta M, Nurzynska D, Di Meglio F,
Castaldo C, Miraglia R, Montagni S, Ciardelli G. Polyurethane-
based scaffolds for myocardial tissue engineering. Interface Focus
2014;4:20130045.
32. Volkmer E, Drosse I, Otto S, Stangelmayer A, Stengele M,
Kallukalam BC, Mutschler W, Schieker M. Hypoxia in static and
dynamic 3D culture systems for tissue engineering of bone. Tis-
sue Eng Part a 2008;14:1331–1340.
33. Volkmer E, Otto S, Polzer H, Saller M, Trappendreher D, Zagar D,
Hamisch S, Ziegler G, Wilhelmi A, Mutschler W, Schieker M.
Overcoming hypoxia in 3D culture systems for tissue engineering
of bone in vitro using an automated, oxygen-triggered feedback
loop. J Mater Sci Mater Med 2012;23:2793–2801.
34. Melchels FPW, Tonnarelli B, Olivares AL, Martin I, Lacroix D,
Feijen J, Wendt DJ, Grijpma DW. The influence of the scaffold
design on the distribution of adhering cells after perfusion cell
seeding. Biomaterials 2011;32:2878–2884.
10 HERNANDEZ-CORDOVA ET AL. INDIRECT THREE-DIMENSIONAL PRINTING OF CARDIAC SCAFFOLDS
